SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Eloxx Pharmaceuticals Posts $5.54M Q3 Net Loss, Reports $56.3M Cash

Eloxx Pharmaceuticals reported a third-quarter 2026 net loss of $5.54 million, or $0.49 per share, and cash and cash equivalents of $56.3 million at September 30. The company dosed the first two patients in its Phase 2b Alport syndrome study and received FDA clearance for its planned ADPKD study. I…

ELOX

Related stories